Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Oxford, UK – 24 July 2013. Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, is offering the research community a snapshot of its user-friendly Genefficiency™ NGS Variant Analysis Report software, with the release of a free-to-download demo version. The interactive report efficiently manages the complete data analysis process for NGS workflows and delivers fully annotated data, allowing the identification of meaningful results in just a few simple mouse clicks.
The demo allows researchers to explore the easy-to-use features of the software with publicly-available sequence data from Tariq et al (2011)1, which identified a novel candidate gene (SHROOM3) for heterotaxy, a severe form of congenital heart disease. It provides researchers with a unique opportunity to experience the interactive report format, discovering what’s possible with OGT’s Genefficiency NGS Services. The report offers rapid filtering options, built-in quality control metrics and the ability to retrospectively analyse the data with additional or new selection criteria.
On completion of all OGT Genefficiency NGS exome and targeted panel projects, customers receive their results pre-loaded into the Genefficiency NGS Variant Analysis Report, so that they can quickly and easily identify relevant data. OGT’s services cover the complete NGS pipeline, from project conception through to the delivery of high-quality, meaningful results via the software, bypassing the bottleneck of complex data analysis.
The Genefficiency NGS Variant Analysis Report is an intuitive solution to NGS data analysis and reporting. Thousands of variations can be filtered within minutes to just a handful requiring further validation — with no requirement for additional bioinformatics resources. Bespoke analysis is easily integrated into the reporting software, allowing variants to be filtered based on biological function or other tailored criteria, for the easy identification of the most significant regions of genetic variation relevant to each individual study. Furthermore, the readily accessible in-depth quality metrics provide maximum confidence that the results are of the highest quality.
To download the demo, register here.
For more information on OGT’s Genefficiency services contact OGT or visit the website.
References:
1. Tariq M, et al (2011). SHROOM3 is a novel candidate for heterotaxy identified by whole exome sequencing. Genome Biol. Sep 21;12(9):R91. doi: 10.1186/gb-2011-12-9-r91.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: contact@ogt.com
W: www.ogt.com ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Help employers find you! Check out all the jobs and post your resume.
